Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note.
Seven cases of endometrial adenocarcinoma patients who had experienced long-term tamoxifen treatments as adjuvant therapy of breast carcinoma, were investigated with respect to estrogen receptor (ER) status. Four cases of endometrial adenocarcinoma without tamoxifen treatment but with a previous history of breast carcinoma were investigated for comparison. One of the 7 and two of the 4 cases were positive for ER immunohistochemically. Thus, the frequency of ER positivity in secondary endometrial adenocarcinoma seemed to be at random among tamoxifen-treated and non-treated breast cancer patients. These results suggest that tamoxifen-mediated human endometrial carcinogenesis may not involve estrogenic pathway(s) but may involve other carcinogenic mechanisms such as DNA adduct formation as shown in rat liver tumorigenesis.
Kuwashima
Y
Y
Department of Pathology, Saitama Cancer Center, Japan.
Kurosumi
M
M
Kobayashi
Y
Y
Tanuma
J
J
Suemasu
K
K
Higashi
Y
Y
Kasamatsu
T
T
Shiromizu
K
K
Matsuzawa
M
M
Kishi
K
K
D000230:Adenocarcinoma / Q000139:chemically induced / Q000737:chemistry*; D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000737:chemistry*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000737:chemistry*; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen